Although the response rate to immunotherapies in unselected CRC is relatively low [14,15], PD-L1 inhibitors have shown good response in advanced CRC and some have been approved for treatment in patients with deficient mismatch repair (dMMR) refractory or metastatic CRC [16,17]. The gene discussed is CD274; the disease is colorectal carcinoma.